公开(公告)号：WO2005040418A2

公开(公告)日：2005-05-06

申请号：PCT/EP2004/011269

申请日：2004-10-08

Applicant: DEUTSCHES KREBSFORSCHUNGSZENTRUM ,  NIEHRS, Christof ,  WU, Wei ,  GLINKA, Andrei ,  KAZANSKAYA, Olga

Inventor： NIEHRS, Christof ,  WU, Wei ,  GLINKA, Andrei ,  KAZANSKAYA, Olga

IPC: C12Q1/68

CPC classification number: C07K16/18 ,  C07K16/22 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C12Q1/6883 ,  C12Q1/6897 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/5041 ,  G01N33/574 ,  G01N33/57492 ,  G01N2500/10

Abstract: The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4(= R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Futrin 1, 2, 3 and/or 4 or (b) the activity of the Futrin 1, 2, 3 and/or 4 protein.

Abstract translation: 本发明涉及用于诊断与编码分泌蛋白Futrin 1,2,3和/或4的基因的异常表达有关的疾病的组合物（= R-Spondin 2,3 ，1和4），例如 与肿瘤或肌肉，肾脏或骨骼疾病有关。 本发明还涉及含有能够修饰（a）编码Futrin 1,2,3和/或4的基因的表达或（b）Futrin 1,2,3的活性的化合物的药物组合物 和/或4种蛋白质。

公开(公告)号：WO2005040418A3

公开(公告)日：2005-11-10

申请号：PCT/EP2004011269

申请日：2004-10-08

Applicant: DEUTSCHES KREBSFORSCH ,  NIEHRS CHRISTOF ,  WU WEI ,  GLINKA ANDREI ,  KAZANSKAYA OLGA

Inventor： NIEHRS CHRISTOF ,  WU WEI ,  GLINKA ANDREI ,  KAZANSKAYA OLGA

IPC: A61K39/00 ,  C07K14/47 ,  C07K14/78 ,  C12Q1/68

CPC classification number: C07K16/18 ,  C07K16/22 ,  C07K16/30 ,  C07K2317/24 ,  C07K2317/54 ,  C07K2317/55 ,  C12Q1/6883 ,  C12Q1/6897 ,  C12Q2600/136 ,  C12Q2600/158 ,  G01N33/5041 ,  G01N33/574 ,  G01N33/57492 ,  G01N2500/10

Abstract: The present invention relates to a composition useful for the diagnosis of diseases associated with aberrant expression of the genes encoding the secreted proteins Futrin 1, 2, 3 and/or 4(= R-Spondin 2, 3, 1 and 4, respectively), e.g. in connection with tumors or diseases of the muscle, kidneys or bones. The present invention also relates to a pharmaceutical composition containing a compound which is capable of modifying (a) the expression of the gene encoding Futrin 1, 2, 3 and/or 4 or (b) the activity of the Futrin 1, 2, 3 and/or 4 protein.

Abstract translation: 本发明涉及可用于诊断与编码分泌蛋白质Futrin 1,2,3和/或4（= R-Spondin 2,3,3和1）的基因的异常表达有关的疾病的组合物， 例如 与肿瘤或肌肉，肾脏或骨骼的疾病有关。 本发明还涉及含有能够修饰（a）编码Futrin 1,2,3和/或4的基因的表达或（b）Futrin 1,2,3的活性的化合物的药物组合物 和/或4蛋白。

公开(公告)号：WO2008046649A1

公开(公告)日：2008-04-24

申请号：PCT/EP2007/009105

申请日：2007-10-19

Applicant: DEUTSCHES KREBSFORSCHUNGSZENTRUM STIFTUNG DES ÖFFENTLICHEN RECHTS ,  NIEHRS, Christof ,  KAZANSKAYA, Olga ,  OKAWARA, Bisei

Inventor： NIEHRS, Christof ,  KAZANSKAYA, Olga ,  OKAWARA, Bisei

IPC: A61K38/17 ,  A61P35/00

CPC classification number: C07K14/475 ,  A61K38/1703 ,  A61K39/3955 ,  C07K14/515 ,  C07K16/18 ,  C07K2317/76 ,  C12N15/1136 ,  C12N2310/111 ,  C12N2310/14 ,  C12N2310/3233 ,  C12Q1/6883 ,  C12Q2600/106 ,  G01N33/74 ,  G01N2800/52 ,  Y10T436/143333

Abstract: The present invention relates to the use of Rspondins, particularly Rspondin2 (Rspo2) or Rspondin3 (Rspo3) or Rspondin nucleic acids, or regulators or effectors or modulators of Rspondin e.g. Rspo2 and/or Rspo3 to promote or inhibit angiogenesis and/or vasculogenesis, respectively. The invention is based on the demonstration that Rspo3 and Rspo2 are angiogenesis promoters, and the identification of Rspo2 and 3 as positive regulators of vascular endothelial growth factor (VEGF). These results indicate a major role for Rspondins, particularly Rspo3 and/or Rspo2 in the signalling system during angiogenesis. The invention also relates to the use regulators or effectors or modulators of Rspondin3, including agonists and antagonists, in the treatment of conditions where treatment involves inhibiting or promoting angiogenesis and/or vasculogenesis.

Abstract translation: 本发明涉及使用Rspondin，特别是Rspondin2（Rspo2）或Rspondin3（Rspo3）或Rspondin核酸，或Rspondin的调节剂或调控子或调节剂。 Rspo2和/或Rspo3分别促进或抑制血管发生和/或血管发生。 本发明基于Rspo3和Rspo2是血管生成启动子的证明，并且将Rspo2和3鉴定为血管内皮生长因子（VEGF）的正调节剂。 这些结果表明Rspondins，特别是Rspo3和/或Rspo2在血管生成过程中信号系统中的主要作用。 本发明还涉及Rspondin3的用途调节剂或效应物或调节剂，包括激动剂和拮抗剂，用于治疗涉及抑制或促进血管生成和/或血管生成的病症。